SMARCAL1 is a candidate therapeutic target for ALT-positive tumors
Certain bone cancers and other tumors lacking telomerase depend on a specific protein for survival, creating a potential vulnerability that could be exploited with new drug combinations.
Using the Cancer Dependency Map and validated across ALT-positive cell lines and osteosarcoma patient-derived xenografts, SMARCAL1 is identified as a top selective dependency factor in telomerase-negative tumors; its loss exacerbates ALT-dependent phenotypes and induces telomeric ssDNA accumulation via PRIMPOL-mediated repriming. This vulnerability could be exploited by combining SMARCAL1 depletion with senolytic agents, offering a novel two-hit therapeutic strategy for >50% of osteosarcomas and other ALT-positive cancers with no current targeted therapies.
What the study was
- Study design
- preclinical_functional_genomics
- Category
- precision_oncology
- Maturity
- Exploratory
- Journal
- Genes & Development
Why it surfaced
Addresses a major unmet need in pediatric/young adult osteosarcoma (5-year OS ~65%) by identifying an actionable dependency in ALT-positive cells; DepMap-driven discovery with mechanistic clarity. Score 7 (N=3, D=1, P=2, E=1) reflecting preclinical design but strong precision oncology/rare disease relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.